Scarica l'app Stockscreener
169.85
1.55%
2.60
Dopo l'orario di chiusura:
169.46
-0.39
-0.23%
Precedente Chiudi:
$167.25
Aprire:
$162.13
Volume 24 ore:
213.95K
Relative Volume:
1.04
Capitalizzazione di mercato:
$6.68B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-73.92
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
+13.86%
1M Prestazione:
-4.35%
6M Prestazione:
+129.34%
1 anno Prestazione:
+159.87%
Intervallo 1D:
$162.00
$176.18
Intervallo di 1 settimana:
$147.00
$176.18
Portata 52W:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
169.85 | 6.68B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - Defense World
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - tipranks.com
Belite Bio (BLTE) Is Up 7.9% After Phase 3 DRAGON Win And $402M OfferingHas The Bull Case Changed? - Sahm
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO now holds 289,736 vested option shares - Stock Titan
Belite Bio (BLTE) CSO gains 144,868-share option vesting - Stock Titan
Belite Bio Jumps on Drug Hopes and Analyst Boost - TipRanks
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - TipRanks
Belite Bio, Inc. ADR Shares Surge on Drug Progress - TipRanks
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - The Manila Times
Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online - Stock Titan
Belite Bio (BLTE) 2025 20-F: Tinlarebant NDA plan and rising losses - stocktitan.net
Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - Barchart.com
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat
(BLTE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan
Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan
Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan
Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan
BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan
Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan
Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan
Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan
Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan
(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily
Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio at Leerink Conference: Tinlarebant’s Promising Trials - Investing.com
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat
Belite Bio Q4 Earnings Call Highlights - Defense World
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - Defense World
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com Nigeria
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):